Ignite Creation Date:
2025-12-24 @ 9:30 PM
Ignite Modification Date:
2026-02-20 @ 6:41 PM
Study NCT ID:
NCT03790332
Status:
COMPLETED
Last Update Posted:
2025-10-21
First Post:
2018-12-12
Is Gene Therapy:
True
Has Adverse Events:
False
Brief Title:
Phase 1/2 Dose Finding and Safety Study of Ibrutinib in Pediatric Subjects With Chronic Graft Versus Host Disease (cGVHD)
Sponsor:
Pharmacyclics LLC.
Organization:
Conditions & Keywords Data
Conditions:
Conditions
| Condition Brief | Condition Text | View |
|---|---|---|
| None | Chronic Graft Versus Host Disease | View |
Keywords:
Keywords
| Keyword Brief | Keyword Text | View |
|---|---|---|
| None | cGVHD | View |
| None | chronic graft versus host disease | View |
| None | PCYC1146IM | View |
| None | Pediatric | View |
| None | GVHD | View |
| None | chronic | View |
| None | 1146 | View |
| None | Pharmacyclics | View |
| None | PCYC | View |
| None | Imbruvica | View |
| None | Ibrutinib | View |
| None | Immunology | View |
| None | graft versus host disease | View |
| None | corticosteroids | View |
| None | prednisone | View |
| None | PCI32765 | View |
| None | PCYC1146 | View |
| None | refractory | View |
| None | new onset graft versus host disease | View |
| None | refractory graft versus host disease | View |
| None | moderate cGVHD | View |
| None | severe cGVHD | View |
| None | moderate chronic graft versus host disease | View |
| None | severe chronic graft versus host disease | View |